Mosaic ImmunoEngineering is a development-stage biotechnology company with no approved products, no revenue from product sales, and no active pipeline. Mosaic's stated focus is developing immunotherapies for cancer treatment, but it currently holds no assets to advance toward that goal. Its original core asset — a license to the cowpea mosaic virus platform technology from Case Western Reserve University — was terminated in March 2024. Since then, Mosaic has been attempting to rebuild its pipeline through an acquisition of clinical-stage cancer therapy assets from Oncotelic Therapeutics, but that deal expired in June 2025 without a definitive agreement. Mosaic has funded itself almost entirely through small convertible note issuances, raising a few hundred thousand dollars at a time from individual investors. The company has earned minimal advisory service income from Oncotelic, but that services agreement expired in early 2025. Mosaic has only two full-time employees and five part-time employees, most of whom have been inactive due to insufficient capital. If Mosaic were to successfully acquire product candidates, its intended model would be to advance those candidates through clinical trials toward FDA approval, commercializing independently in the U.S. or through pharmaceutical partners internationally — but this remains entirely aspirational given the current absence of a pipeline, capital, or operational infrastructure.